NCT03855228View on ClinicalTrials.gov

Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)

PHASE3CompletedINTERVENTIONAL

Enrollment

704

Participants

Timeline

Start Date

March 1, 1995

Primary Completion Date

August 7, 1995

Study Completion Date

August 7, 1995

Conditions

Rhinitis, Allergic

Interventions

DRUG

Mometasone furoate nasal spray (MFNS)

Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.

DRUG

Loratadine

Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.

DRUG

Placebo nasal spray

Daily dose of placebo administered as a nasal spray for 15 days.

DRUG

Placebo tablet

Daily dose of placebo administered as an oral tablet for 15 days.

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT03855228 - Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145) | Biotech Hunter | Biotech Hunter